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Abstract 
Extrahepatic disease manifestations are common in chronic hepatitis C 
virus (HCV) infection. The mechanism of HCV-related lymphoproliferative 
disorders is not fully understood. Recent studies have found that HCV in 
peripheral blood mononuclear cells (PBMCs) from chronically infected 
patients is mainly associated with CD19+ B cells. To further elucidate this 
preferential association of HCV with B cells, we used in vitro cultured virus 
and uninfected PBMCs from healthy blood donors to investigate the 
necessary serum components that activate the binding of HCV to B cells.  
First, we found that the active serum components were present not only in 
HCV carriers, but also in HCV recovered patients and HCV negative healthy 
blood donors and that the serum components were heat labile.  Second, 
the preferential binding activity of HCV to B cells could be blocked by anti-
complement C3 antibodies.  In experiments with complement-depleted 
serum and purified complement proteins, we demonstrated that 
complement proteins C1, C2, and C3 were required to activate such binding 
activity. Complement protein C4 was partially involved in this process.  
Third, using antibodies against cell surface markers, we showed that the 
binding complex mainly involved CD21 (complement receptor 2), CD19, 
CD20, and CD81; CD35 (complement receptor 1) was involved but had 
lower binding activity.  Fourth, both anti-CD21 and anti-CD35 antibodies 
could block the binding of patient-derived HCV to B cells. Fifth, 
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complement also mediated HCV binding to Raji cells, a cultured B cell line 
derived from Burkitt’s lymphoma.  Conclusion: In chronic HCV infection, 
the preferential association of HCV with B cells is mediated by the 
complement system, mainly through complement receptor 2 (CD21), in 
conjunction with the CD19 and CD81 complex.  
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Introduction 
An estimated 180 million individuals are infected with hepatitis C virus (HCV) 
worldwide (1). More than 75% of HCV infections become persistent and may 
eventually lead to cirrhosis and hepatocellular carcinoma in 20% - 40%.  A broad 
spectrum of extrahepatic manifestations is also associated with chronic HCV 
infection, including mixed cryoglobulinemia, cutaneous vasculitis, and B-cell non-
Hodgkin’s lymphoma (B-NHL) (2-5). Although there are several reports 
suggesting extrahepatic replication of HCV, particularly in PBMCs, even in some 
patients who appear to have resolved their infection (6-9), the existence of  
extrahepatic reservoirs of HCV replication remains highly controversial (10, 11). 
 
Although the major site of HCV replication is in the liver, HCV RNA has been 
detected in association with peripheral blood mononuclear cells (PBMCs)  (7, 10), 
and is particularly enriched in CD19+ B cells (10, 12, 13). Several factors have 
been shown to play important roles in HCV entry into susceptible cells (14-18), 
including CD81, scavenger receptor SR-BI, and the tight-junction protein 
Claudin-1.  All three entry factors are required for infection of Huh-7.5 cells by 
cell culture-produced infectious HCV particles (16).  However, all PBMC subsets 
lack at least one of these known HCV entry factors (16). CD81 is a widely 
distributed cell-surface tetraspanin that participates in different molecular 
complexes on various cell types, including B, T, and natural killer cells (16) and 
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has been proposed as the primary mediator of HCV binding to B cells (17, 18).   
In human B cells, CD81 is known to form a costimulatory complex with CD19 and 
complement receptor 2 (CD21) (19). Co-ligation of the B cell antigen receptor 
(BCR) with this costimulatory complex can lower the threshold required for BCR-
mediated B cell proliferation (20). Because all major subsets of PBMCs have 
high level expression of CD81 (18), CD81 alone could not account for the  
preferential association of HCV with B cells. 
 
In this study, we used cell culture-produced HCV particles, pre-incubated with 
serum components plus various factors, followed by mixing with PBMCs from 
healthy blood donors. After separating PBMC into B cell and non-B cell fractions 
by CD19 magnetic microbeads, quantification of HCV RNA was carried out by 
real-time reverse-transcription polymerase chain reaction (qPCR) to measure the 
quantities of HCV binding to B cells.  We sought to investigate the mechanism of 
preferential association of HCV with B cells in PBMCs from chronic HCV carriers, 
and to identify specific cell surface receptors involved in the binding process.  
 
Patients and Methods 
Patients:  
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Consenting blood donors identified as anti-HCV positive by enzyme 
immunoassay at the time of routine blood donation at the Department of 
Transfusion Medicine, National Institutes of Health (NIH) or the Greater 
Chesapeake and Potomac Region of the American Red Cross were enrolled in 
an NIH prospective study of the natural history of HCV infection (10). Ethics 
committees of the American Red Cross and the NIH approved the study protocol 
in accordance with the Declaration of Helsinki and the study has been reviewed 
annually by an NIH Institutional Review Board (NIH Protocol 91-CC-0017). All 
subjects gave written informed consent to participate in the study.  
 
Methods: 
A detailed description of methods used for cell culture, in vitro RNA synthesis, 
HCV production in cell culture, conversion of plasma to serum, PBMC isolation, 
part of in vitro HCV binding assay, and HCV detection can be found in 
Supporting Information. 
 
In vitro HCV binding assay   
In a standard binding assay, 3 ml of virus (1x107 genomic copies for HCV 
genotype 1a virus) was mixed with 100 µl of serum sample (about 20-25 CH50 
units) to initiate complement activation and incubated at 25ºC for 1 h or at 37ºC 
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for 0.5 h, followed by adding 2 ml of PBMCs (4-5x107 cells) to the mixture and 
incubating for 1 h. The reaction was carried out in 50 ml sterile tubes with 
occasional mixing. After incubation, the cells were pelleted by centrifugation, 
washed once with 10 ml 1X PBS, pH7.4, centrifuged again, and re-suspended in 
400 µl of MACS buffer (Miltenyi Biotec Inc., Auburn, CA) supplemented with 
0.5% bovine serum albumin. The cells were mixed with 100 µl of mouse anti-
human CD19 magnetic microbeads and incubated at 4ºC for 20 min. The cells 
were then diluted with 10 ml MACS buffer, collected by centrifugation, and re-
suspended in 1 ml MACS buffer. The cell suspension was applied to a MS 
column (Miltenyi Biotec Inc., Auburn, CA) on a magnetic field separator. The 
column was washed three times with 1 ml MACS buffer each time. The column 
was separated from the magnetic stand and placed on a 2 ml sterile tube. The 
CD19+ B cells were flushed  from the column with 1 ml MACS buffer, collected 
by centrifugation, and re-suspended in 650 µl of RNeasy Plus lysis buffer 
(Qiagen, Chatsworth, CA) supplemented with 1% 2-mercaptoethanol. RNA 
isolation was carried out by using RNeasy Plus mini kit (Qiagen, Chatsworth, CA) 
according to the manufacturer’s instructions, and each sample was eluted from 
the column with 50 µl of nuclease-free water (Thermo Fisher Scientific, Waltham, 
MA) supplemented with 1.0 mM dithiothreitol and 200 unit/ml RNAsin (Promega, 
Madison, WI). 
 
Statistical analysis 
Page 8 of 51
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
9 
 
Quantitative analysis of HCV genome copy number assessed by qPCR is 
expressed as the mean ± standard deviation. An unpaired Student’s t-test was 
used to determine the statistical significance. Values of P < 0.05 were judged 
significant. Data analysis and graphs were performed with GraphPad Prism 5 
(GraphPad Software, La Jolla, CA).  
 
RESULTS 
 
Serum components from both HCV recovered patients and healthy blood 
donors can promote HCV binding to B cells. 
 To investigate the mechanism of preferential association of HCV with B cells in 
PBMC from chronic patients, we used in vitro cultured HCV virus (H77s, HCV 
genotype 1a) and B-cell enriched fractions from healthy donors to determine 
which serum components are necessary for promoting HCV binding to B cells. In 
the absence of serum, binding of HCV particles derived from in vitro cell culture 
was minimal in our in vitro assay system (data shown in Fig.1 legend and Fig. 2). 
When cell culture-produced HCV particles were pre-incubated with human serum 
samples, the viral particles attached to B cells with more than 100-fold efficiency 
as compared to that without serum treatment. As shown in Fig.1, serum samples 
from both HCV recovered patients and heathy blood donors contained such 
enhancing activity.  This result indicated that the enhancement of HCV binding to 
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B cells by serum was independent of HCV infection and inherent in normal 
human serum. We also found significant variation among individuals of the 
enhancing activity present in their serum samples. 
 
Heat-labile components in human serum promote the binding of HCV to B 
cells. 
During the investigation period, we observed that the activity promoting HCV 
binding to B cells present in the serum samples was quickly lost even when the 
serum samples were stored at 4ºC.  Therefore, we measured the sensitivity of 
HCV binding activity to B cells by incubating serum samples at 56ºC for 30 min 
first before mixing with virus. About 90% of HCV binding activity to B cells was 
lost after heat treatment as compared to the untreated serum samples (Fig. 2).  
 
Antibodies against complement C3 protein can block HCV binding to B 
cells. 
Since complement activity is well known for heat sensitivity, we tested whether 
the available antibodies against complement C3 protein could block the binding 
of HCV to B cells in our assay system. As shown in Fig.3, several anti-C3 
antibodies, such as anti-C3 (C-4), anti-C3 (2898), and anti-C3d, had significant 
blocking activity against HCV binding to B cells, particularly, anti-C3d showed the 
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strongest blocking activity. However, because of the abundance of C3 protein in 
serum, when lowering the amount of C3d antibody, the blocking activity was 
gradually decreased (Supporting Fig. S1). Anti-C3 (B-9) antibody did not show 
blocking activity against HCV binding to B cells in our assay system. This may be 
because the epitope recognized by this antibody was not accessible in this assay. 
 
Purified complement proteins added to the complement-depleted serum 
can restore HCV binding to B cells.    
To further demonstrate the complement system is responsible for promoting the 
binding of HCV to B cells, we obtained several commercially available 
complement-depleted serum samples and purified complement proteins to 
reconstitute the binding experiment. As shown in Fig. 4, when binding of HCV 
was performed with C1, C2 or C3 depleted serum samples, the binding activity 
could hardly be detected. After adding the respective purified complement protein 
back to the reaction mixture, the binding activity of HCV to B cells was restored. 
In the absence of serum, none of the purified complement proteins alone had the 
ability to promote HCV binding to B cells. These results suggested that 
complement C1, C2, and C3 proteins are absolutely required for activating HCV 
to attach to B cells. When complement C4 depleted serum was tested, about 
40% binding activity was detected as compared to the complete system with C4 
depleted serum plus purified C4 protein (Fig. 4). Purified C4 protein alone did not 
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promote HCV binding to B cells. Therefore, complement C4 plays a lessor role in 
the binding of HCV to B cells compared to complement C1, C2 and C3. These 
results indicated that the classical complement activation pathway is involved in 
promoting the binding of HCV to B cells.  When we mixed purified proteins of C1, 
C2, C3, and C4 together in the absence of serum, we were able to show 
enhancement of HCV binding to B cells (Supporting Fig. S2). Using complement 
C5 depleted serum and purified C5 protein to assay the HCV binding activity to B 
cells, demonstrated that C5 is not required for HCV binding to B cells. Indeed, 
when excess of C5 protein was added to the C5-depleted serum, the binding of 
HCV to B cells was significantly decreased (Fig. 4).  
 
Receptors involved in complement-mediated HCV binding to B cells. 
The above results indicated that the preferential association of HCV with B cells 
in PBMC from chronically infected patients is likely mediated by the complement 
system.  In B cells, complement receptor 2 (CD21) is most abundant and usually 
forms a complex with CD19 and CD81, followed by complement receptor 1 
(CD35). Using a battery of antibodies against complement-related receptors, we 
demonstrated that anti-CD21 had the strongest blocking activity for HCV binding 
to B cells (Fig. 5); this was consistent at varying concentrations of antibody 
ranging from 1 µg to 10 µg (Supporting Fig. S3 and S4). In addition, we showed 
that CD19 (Supporting Fig. S5) or CD20 (Fig. 5) are also involved in HCV binding 
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to B cells. For CD81, about 60% (6 out of 10) of PBMCs isolated from healthy 
blood donors showed inhibitory activity upon treatment of PBMC with anti-CD81.   
                     
Anti-CD21 and anti-CD35 antibodies can block B cell binding of HCV 
viruses derived from chronically infected patients. 
To demonstrate that the preferential binding of HCV to B cells mediated by the 
complement system is not limited to cell culture derived virus, we repeated the B-
cell binding experiments using the serum from three chronically infected patients 
as the source of virus and complement . In patients #1 and #2, both anti-CD21 
and anti-CD35 antibodies inhibited HCV binding to B cells with anti-CD21 
showing stronger activity. In patient #3, only anti-CD21 showed significant 
inhibitory activity (Fig. 6).  
 
Complement-mediated HCV binding to B cells using in vitro cultured HCV 
1a and HCV 2a viruses. 
We further investigated whether complement-mediated HCV binding to B cells 
could be demonstrated using other commonly used cell culture-produced viruses, 
specifically JFH1 virus (HCV genotype 2a) and chimeric JFH1/1a virus. As 
shown in Fig. 7, both these well-characterized viral strains became much more 
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efficiently bound to B cells (P < 0.0001) after mixing with complement-active 
serum samples.  
 
Enhanced HCV binding to Raji cells was also mediated by complement 
system. 
We also investigated whether complement-mediated HCV binding to B cells 
could be demonstrated by replacing human B cells with Raji cells, a cultured B 
cell line derived from Burkitt’s lymphoma. As shown in Fig. 8A, cell culture-
produced HCV became much more efficiently bound to Raji cells after treatment 
of virus with complement-active serum samples either at 25oC or at 37oC as 
compared to the untreated samples. We also demonstrated that pre-incubation of 
Raji cells with anti-CD21 or anti-CD19 antibody could block the subsequent 
binding of complement-activated HCV to the cells (Fig. 8B). Pre-incubation of 
Raji cells with anti-CD81 antibody did not prevent complement-activated HCV 
binding to the cells (Fig. 8B), as we had also observed in PBMCs isolated from 
40% of healthy blood donors.  
 
Discussion  
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In our previous study of the association of HCV with PBMCs, we found no 
evidence that HCV replicates in PBMCs (10), but rather that HCV binds to 
PBMCs and preferentially to B cells. Further, we found that normal PBMCs could 
be made to simulate PBMCs from HCV infected patients simply by mixing them 
with HCV-positive plasma. Thus, it appeared that HCV could adhere to PBMC/B- 
cells without necessarily infecting them, suggesting that the binding was a more 
generalized phenomenon of B-cell interactions rather than a specific effect of 
HCV.   
   
To elucidate the mechanism of preferential association of HCV with B cells, we 
began the investigation by using in vitro cell culture produced HCV particles 
mixed with PBMCs from healthy donors for in vitro binding assays, followed by 
fractionation of CD19+ B cells and HCV quantification by qPCR. In the absence 
of exogenous serum factors, there was negligible binding of culture-produced 
HCV particles to B cells.  However, upon pre-incubation of culture-produced HCV 
particles with serum, HCV binding to B cells was increased by more than two 
orders of magnitude compared to virus in the absence of serum. The essential 
serum factors were found to be heat-labile and present in both healthy blood 
donors and HCV recovered patients, suggesting that complement might be 
integral to the binding process. 
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By using various antibodies against complement C3 proteins in the B-cell binding 
assays, we demonstrated that several anti-C3 mouse monoclonal antibodies, 
particularly anti-C3d antibody, effectively blocked the binding of HCV to B cells. 
C3d is the surface-bound end–product of the proteolytic cleavage of C3b 
deposited on invading microorganisms during the complement activation process 
that splits C3 to C3a and C3b (21-25). In reconstitution experiments with 
complement-depleted serum samples and the respective purified complement 
proteins, we demonstrated that the preferential binding of HCV particles to B 
cells in PBMCs is indeed mediated by the complement system as complement 
components involved in the classical pathway (C1q, C2, C3 and C4) were 
required for the binding of HCV particles to B cells. In addition, the alternative 
pathway and the mannose-binding lectin pathway of complement activation could 
also be involved in this process (22). The generation of C3d is essential for the 
opsonization of HCV particles leading to their attachment to B cells. We propose 
that C3d attached to viral particles will have high affinity for complement receptor 
2 (CR2; CD21) on the surface of B cells. CR2 is highly expressed in B cells and 
follicular dendritic cells (22, 24). In our current assay system, there was no 
significant change of HCV genomic copy numbers in the culture supernatant 
before and after complement treatment as determined by qPCR (data not shown), 
which implies that HCV particles are not lysed, but rather opsonized by 
complement activation. Although previous reports have shown that HCV core 
protein can bind to gC1q receptor (gC1qR) specific for the globular heads of the 
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C1q protein (26),  this mechanism would  not explain why HCV particles are 
preferentially bound to B cells since this receptor is widely distributed in all 
leukocyte subsets and platelets (27). Further, the preferential binding of HCV to 
B cells only happens when exogenous serum with complement activity is added 
to the virus supernatant and thus is not related to a virus-specific protein per se. 
In the C5-depleted serum reconstitution experiment, we found that C5 protein is 
not required for the preferential binding of HCV to B cells. Again this indicates 
that HCV particles are opsonized, and not lysed through a membrane attack 
complex. However, when excess of the purified C5 protein was present in 
reconstituted C5-depleted serum, the binding of HCV to B cells was significantly 
decreased suggesting that complement-mediated viral lysis may have occurred 
(Fig 4).  
 
There are at least ten receptors for complement components, fragments, and 
complexes (22, 27). To further elucidate the mechanism of preferential binding of 
HCV to B cells, we used various antibodies against cell surface receptors in the 
assay system to assess the effectiveness of each antibody in blocking HCV 
binding to B cells. As shown in Fig. 5, anti-CD21 displayed the strongest activity 
in blocking HCV binding to B cells, followed by anti-CD20, anti-CD35, and anti-
CD81. CD21 is complement receptor 2 (CR2), and the receptor for C3d (27).  
CD21 usually forms a complex with CD19 and CD81 on the surface of B cells 
(28). CD35 is complement receptor 1 (CR1), and it has dual roles as complement 
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receptor and complement regulator (27). The ligands for CR1 are C3b and C4b. 
In this study, we found that anti-CD81 antibody only blocked HCV binding to B 
cells in 60% of PBMCs tested from 10 individuals. This could be due to 
polymorphic CD81 antigen expression on B cells from different individuals. Anti-
CD81 antibody also did not block HCV binding to Raji cells (Fig. 8B). The 
preferential binding of HCV to B cells was shown not only for HCV particles 
produced in cell culture, but also for HCV particles derived directly from three 
chronically infected patients. Whether using culture-derived or patient-derived 
HCV, binding to B cells was blocked more efficiently by anti-CD21 (complement 
receptor 2) than by anti-CD35 (complement receptor 1). Similar finding of human 
immunodeficiency virus 1 (HIV-1) binding to B cells through CD21-complement 
interactions has been reported (29). 
 
The complement system plays a central role in innate immune defense and 
consists of both soluble factors and cell surface receptors that interact to sense 
and respond to a wide range of invading microorganisms. Activation of 
complement system has been demonstrated  during infection by several 
enveloped viruses including HIV-1 (24), herpesvirus (30), Ebola virus (31), and 
influenza virus (32). However, these viruses have also evolved escape 
mechanisms to evade the complement system by incorporating host regulators of 
complement activation into their viral envelopes and, as a result, escape 
antibody-dependent complement-mediated virus lysis (30, 33). Complement 
Page 18 of 51
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
19 
 
activation upon HCV infection has been implicated in several studies (34-36). In 
addition, CD55 and CD59, regulators of complement activation, were shown to 
be incorporated into HCV virions (37, 38), which led to resistance to complement-
mediated antibody-dependent virolysis. In the present study, we demonstrated 
that HCV particles either produced by in vitro cell culture system or directly from 
chronic HCV patients were opsonized, but not lysed by complement activation, 
which eventually led to preferential association of HCV particles with B cells in 
PBMC. Although not investigated in this study, in chronic HCV patients, 
complement receptor 1/CD35 on erythrocytes may also play a key role in 
transporting complement-mediated, opsonized HCV immune-complexes. In this 
study, we mainly investigated antibody-independent activation of the complement 
system by HCV.  In chronic HCV infection, antibody-dependent complement 
activation may play a more complex role and interplay with many other types of 
cells, as seen in HIV infection (24). 
 
Epidemiological studies have demonstrated an increased risk of developing B-
cell non-Hodgkin lymphoma (B-NHL) in patients with chronic HCV infection (39, 
40). B-NHL subtypes frequently associated with HCV are marginal zone 
lymphoma, lymphoplasmacytic lymphoma, and diffuse large B-cell lymphoma. 
The most convincing evidence for a causal relationship between HCV infection 
and lymphoma development is the observation of B-NHL regression after HCV 
eradication with interferon-α monotherapy or in combination with ribavirin (39, 40). 
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However, the strength of the association shows great geographic discrepancies, 
with higher relative risk in countries with high HCV prevalence. Three general 
hypotheses have been proposed to elucidate HCV-induced lymphomagenesis 
(39): 1) Continuous external stimulation of lymphocyte receptors by viral antigens 
throughout persistent infection; 2) HCV replication in B cells with oncogenic effect 
mediated by intracellular viral proteins; 3)  permanent B-cell damage by mutation 
of tumor suppressor genes caused by a transiently present intracellular virus (41). 
The lymphoma subtypes associated with HCV infection originate from germinal 
center or post-germinal center lymphocytes, suggesting a possible antigen-driven 
proliferation (40). Indeed, a monoclonal/oligoclonal B-cell expansion has been 
shown in circulating B cells, as well as in the bone marrow or intrahepatic B cells 
of chronic HCV patients (42). However, the strongly biased immunoglobulin gene 
usage by abnormal B cells in HCV-associated mixed cryoglobulinemia (43) and 
in HCV-associated lymphomas (44, 45), as well as the inability of lymphoma 
BCRs from patients with B-NHL and chronic HCV infection to bind HCV antigens 
(46), may indicate that lymphoma formation in HCV infection is a complex 
process in which persistent antigenic stimulation through complement- mediated 
binding plays only an indirect, and as yet undefined role. Our results support the 
notion that chronic HCV infection can potentially promote lymphomagenesis 
through complement-mediated preferential binding of HCV to B cells, which 
generates a complex by combining C3d-tagged HCV with CD19 and CD81. This 
complex can then bring B-cell antigen receptors together into lipid rafts and lower 
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the threshold for B-cell activation and proliferation (47, 48). Further investigation 
of signaling pathways involved in complement-mediated HCV binding to B cells is 
warranted.  
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Figure legends 
Fig. 1.  Serum samples from both healthy blood donors and HCV recovered 
subjects can promote HCV binding to B cells. Ten million genomic copies of HCV 
1a (H77s) in 3 ml medium were incubated with 100 µl serum sample at room 
temperature for 1 h, followed by mixing with 2 ml PBMCs (2.5x107 cells/ml) in 
complete RPMI medium. The reaction was carried out at 37ºC for 2 h. The cells 
then were processed for separation into B and non-B fractions by using CD19 
magnetic microbead column purification as described in Methods section. A 
negative control that did not incubate virus with serum was included in this study 
but not plotted in this figure; this control had an HCV viral load on B cells of 411 
copies per µg total RNA. Each value represents the mean of triplicate 
determinations. 
 
Fig. 2.  Heat-labile components in human serum promote the binding of HCV to B 
cells. Ten million genomic copies of HCV 1a (H77s) in 3 ml medium were 
incubated with 100 µl serum sample or heat-inactivated serum sample (56ºC for 
30 min) at room temperature for 1 h, followed by mixing with 2 ml PBMCs 
(2.5x107 cells/ml) in complete RPMI medium. The reaction was carried out at 
room temperature (25ºC) for 1 h. The cells then were processed for HCV 
quantification as described in Methods section. Each value represents the mean 
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± SD of 9 determinations. The experiments were repeated twice with similar 
results using PBMCs from two different donors. 
 
Fig. 3.  Antibodies against complement C3 protein can block HCV binding to B 
cells. Twenty-five µl serum sample was incubated with 20 µg of the indicated 
mouse monoclonal antibody (clones C4, B9, and 2898) against complement C3 
protein and C3d (clone 003-05) at 25ºC for 30 min, followed by mixing with virus 
and incubating at 25ºC for 1 h. After mixing with PBMC, the mixture was 
incubated at 25ºC for one more hour. The cells then were processed for HCV 
quantification as described in Methods section. The most potent inhibitory of 
binding was observed with anti-C3d.  Each value represents the mean ± SD of 6 
determinations. The experiments were repeated three times with similar results 
using PBMCs from three different donors. 
 
Fig. 4.  Purified complement proteins C1q, C2, C3, and C4 added to the indicated 
complement-depleted (Dpl) serum can restore HCV binding to B cells. Ten 
million genomic copies of HCV 1a (H77s) in 3 ml medium were incubated with 
100 µl of the indicated complement-depleted serum sample or complement-
depleted serum sample plus the indicated purified complement protein, or 
purified complement protein only. After 1h incubation at 25ºC, 2 ml PBMCs 
(2.5x107 cells per ml) in complete RPMI medium was added. The reaction was 
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carried out at room temperature (25ºC) for 1 h. The cells then were processed for 
HCV quantification as described in Methods section. All experiments were 
repeated twice with similar results using PBMCs from two different donors. Each 
value represents the mean ± SD of 6 determinations.  
 
Fig. 5.  Receptors involved in complement-mediated HCV binding to B cells. Two 
ml of PBMCs (2.5x107 cells/ml) were incubated with 10 µg of the indicated 
antibody at 25ºC for 0.5 h; followed by mixing with 3 ml of activated virus (pre-
incubation with serum for 1 h at 25ºC, 1x107 genomic copies total), and 
incubating at 25ºC for 1 h. The cells then were processed for RNA isolation and 
HCV quantification as described in Methods section. **: P < 0.01, ***: P < 0.001, 
****: P < 0.0001; when the reduction of HCV binding to B cells by the indicated 
antibody was compared to antibody isotype control. Each value represents the 
mean ± SD of 6 determinations. The experiments were repeated three times with 
similar results using PBMCs from three different donors. CD11b is part of 
complement receptor 3, CD20 is one of major B cell markers, CD21 is also 
known as complement receptor 2, CD32 is receptor for Fc fragment of 
immunoglobulin G, CD35 is complement receptor 1, and CD55 is membrane-
bound decay-accelerating factor for convertases of complement system. 
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Fig. 6.  Anti-CD21 and anti-CD35 antibodies can block the binding of HCV 
viruses from chronically infected patients to B cells.  Two ml of PBMCs (2.5x107 
cells/ml) were incubated with 10 µg of the indicated antibody at 25ºC for 0.5 h; 
followed by mixing with 3 ml of the indicated 15-fold diluted virus (pre-incubation 
for 0.5 h at 25ºC, 3-5x106 genomic copies total), and incubating at 25ºC for 1 h. 
The cells then were processed for RNA isolation and HCV quantification as 
described in Methods section. Each value represents the mean ± SD of 6 
determinations. The experiments were repeated twice with similar results using 
PBMCs from two different donors. 
 
Fig. 7.  Complement-mediated HCV binding to B cells worked on in vitro cultured 
HCV 1a and HCV 2a viruses. Three ml of the indicated virus (HCV1a, 1x107 
copies total; HCV2a, 1x108 copies total; JFH1/1a, 3x107 total) were treated either 
with 100 µl medium only as control or 100 µl serum at 25ºC for 1 h, followed by 
mixing with 2 ml PBMCs (2.5x107 cells per ml) in complete RPMI medium. The 
reaction was carried out at room temperature (25ºC) for 2 h. The cells then were 
processed for HCV quantification as described in Methods section. ****: P < 
0.0001 when compared to without serum treatment for each virus. Each value 
represents the mean ± SD of 6 determinations. 
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Fig. 8.  Complement-mediated HCV binding to Raji cells. (A) HCV genotype 1a 
virus in 3 ml medium was incubated with 100 µl serum sample or medium only at 
25ºC for 1 h, followed by mixing with 2 ml of Raji cells (1x106 cells/ml) and 
incubating at the indicated temperature for 1 h.  (B)  2 ml of Raji cells (1x106 
cells/ml) were incubated with 10 µg each of the indicated antibody at room 
temperature for 30 min,  followed by mixing with 3 ml of complement-activated 
HCV genotype 1a  virus (pre-incubation with serum for 1 h at 25ºC, 1x107 
genomic copies per reaction), and incubating at 25ºC for 1 h. After incubation, 
the cells were pelleted, washed two times with complete RPMI medium, and 
processed for RNA isolation and HCV quantification as described in Methods 
section. Each value represents the mean ± SD of 6 determinations. 
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Supplementary Information 
Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by 
Complement System 
Richard Y. Wang, Patricia Bare, Valeria De Giorgi, Kentaro Matsuura, Kazi Abdus 
Salam, Teresa Grandinetti, Cathy Schechterly, Harvey J. Alter 
 
Supporting Methods: 
Cell culture  
The human hepatoma cell line, Huh7.5.1 was obtained from Dr. Francis V. Chisari (1). 
Huh7.5.1 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(Thermo Fisher Scientific, Waltham, MA) supplemented with 10% heat inactivated fetal 
bovine serum, 2 mM L-glutamine, 10 mM HEPES, pH7.2, 100 unit/ml penicillin, 100 
µg/ml streptomycin, and 1% non-essential amino acids (Thermo Fisher Scientific, 
Waltham, MA) in a humidified 37°C, 5% CO2 incubator. PBMCs and Raji cells were 
cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine 
serum, 2 mM L-glutamine, 100 unit/ml penicillin, and 100 µg/ml streptomycin (complete 
RPMI medium). 
In-vitro RNA synthesis 
The plasmid pH77-S, which carries a full length HCV1a sequence with five cell culture-
adaptive mutations was kindly provided by Dr. Stanley Lemon (2). The plasmid was 
linearized with XbaI restriction enzyme and purified by Qiagen PCR purification kit. In 
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vitro transcribed RNA, using the MEGA-script T7 kit (Thermo Fisher Scientific, Waltham, 
MA), was purified with Qiagen RNA clean up kit. The RNA pellet was aliquoted and 
stored at -80°C until use. 
HCV production in cell culture 
1.4 µg of HCV1a (H77S) full length RNA was transfected into 2x105 Huh7.5.1 cells per 
well in 6-well plates by using mRNA boost reagent and TranslT-mRNA reagent (Mirus, 
MIR2250) according to the manufacturer's instructions. Six hours after transfection, the 
cells were trypsinized, washed once with complete DMEM medium without antibiotics, 
and collected by centrifugation. Cells were seeded into 25x150mm culture dishes at 
1.2x106 cells per dish with 50 ml complete DMEM medium without antibiotics. After 
incubation for 6 days, the culture supernatant was collected and filtered through 0.45µm 
sterile filtration units. The filtrates were aliquoted and stored at -80oC before use. The 
virus producing cells were continuously sub-cultured every 3-4 days for 21 days post 
transfection by seeding 4x106 cells per 25x150mm culture dish with 50 ml complete 
DMEM medium and collecting the culture supernatant after 72 h incubation. For the 
production of HCV genotype 2a virus, 5x106 Huh-7.5.1 cells in each 25x150mm culture 
dish were infected with JFH1 virus at MOI=0.1. The culture supernatant was collected 
96 h post infection and centrifuged at 1,800 rpm for 10 min. The supernatant was 
filtered through 0.45µm sterile filtration units. The filtrates were aliquoted and stored at -
80oC before use. For the production of JFH1/1a chimeric virus, 3x106 Huh-7.5.1 cells in 
each 25x150mm culture dish were infected with JFH1/1a virus at MOI=0.1. After 96 h 
infection, the cells were sub-cultured at 7-8x106 cells per 25x150mm culture dish with 
50 ml complete DMEM medium. The culture supernatant was collected 24 h later and 
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centrifuged at 1,800 rpm for 10 min. The supernatant was filtered through 0.45µm sterile 
filtration units. The filtrates were stored at -80oC before use. 
Conversion of plasma samples to serum samples 
Some HCV patients’ blood samples and heathy blood donor samples were received as 
plasma samples. To convert plasma samples to serum samples, CaCl2 was added first 
to the plasma samples at 10 mM final concentration, mixed, and followed by adding 
thrombin (Sigma-Aldrich, St. Louis, MO) at final 0.1unit/ml.  The samples were 
incubated at 37oC for 0.5 h, followed by incubating at room temperature for 0.5 h, and 
then stored at -20oC overnight.  The samples were thawed in a 37oC water bath, and 
the clots were removed and squeezed for residual fluid using sterile forceps in a 
biosafety hood.  The serum samples were further incubated in ice for one hour.  If no 
clot was detected, 1 ml aliquots were prepared and stored at -80oC. 
PBMCs and PBMC subset separation  
PBMCs were isolated by Ficoll-Paque density gradient centrifugation from buffy coat. 
Each buffy coat (about 18-30 ml) was diluted with 1X PBS, pH7.4 to 120 ml, and divided 
equally into four sterile 50 ml conical tubes. Each tube was then underlay with 15 ml of 
Ficoll-Paque Plus solution (GE Healthcare Life Sciences, Marlborough, MA), and 
centrifuged at 400 x g for 30 min at 25°C. The lymphocytes were collected from the 
interphase layer and washed twice with 1X PBS, pH7.4. The cells were pelleted by 
centrifugation at 400 x g and 200 x g for 10 min each at 25°C for the first wash and the 
second wash, respectively. The cells were further washed once with complete RPMI 
medium and collected by centrifugation at 200 x g for 10 min at 25°C. The B cell subset 
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was purified by positive selection using MACS magnetic beads coated with anti-human 
CD19 antibody (Miltenyi Biotec Inc., Auburn, CA). The efficiency of separation was > 
85% for B cells as confirmed by FACS analysis (BD Biosciences, San Diego, CA). For 
isolation of untouched B cells from PBMCs, human B cell isolation kit II (Miltenyi Biotec 
Inc., Auburn, CA) was used according to the manufacturer’s instructions. 
In vitro HCV binding assay 
For assessing the effect of anti-complement C3 antibodies on blocking HCV binding to 
B cells, 25 µl of complement active serum sample was mixed with 10-20 µg each of 
anti-C3 antibodies as indicated in the figure legend and incubated at 25°C for 30 min 
before adding 3 ml virus to the reaction mixture. All the anti-C3 antibodies used in this 
study were from Santa Cruz Biotechnology (Dallas, TX). For conducting HCV binding 
assays using complement depleted sera reconstituted with purified complement 
proteins, 100 µl of the indicated complement-depleted serum was used for each 
reaction. All the complement-depleted sera and the purified complement proteins used 
in this study were obtained from Complement Technology (Tyler, TX). To measure the 
effect of antibodies against various cell surface receptors on HCV binding to B cells, 2 
ml of PBMCs (4-5x107 cells) or 2 ml of untouched B cells (2-4x106 cells) were incubated 
with 10 µg of mouse monoclonal antibodies against the indicated receptors at 25°C for 
30 min, followed by adding 3 ml of complement activated virus and incubating for 1 h. 
All the antibodies for blocking cell surface receptors used in this study were obtained 
from BD Biosciences (San Diego, CA) except that a few anti-CD19 and anti-CD81 
antibodies from Santa Cruz Biotechnology (Dallas, TX) were also tested. The clone 
numbers for antibodies from BD Biosciences are as follows: CD11b, ICRF44; CD19, 
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HIB19; CD20, 2H7; CD21, 1048; CD32, 3D3; CD35, E11; CD55, IA10; and CD81, JS-
81. The clone numbers for antibodies from Santa Cruz Biotechnology are as follows: 
C3, C-4, B-9 and 2898; C3d, 003-05; and CD81, 1.3.3.22.  C3 (C-4) and C3 (B-9) are 
raised against amino acids 541-840 of human C3. C3 (2898) is raised against the C-
terminus of human C3. C3d (003-05) is raised against full length native C3 of human 
origin. The epitope mapping for anti-CD21 and anti-CD35 has been previously reported 
(3, 4). For determination of HCV binding to Raji cells, Raji cells were cultured in 
complete RPMI medium until the cell density reached to 1-2x106 cells per ml. The cells 
were then collected by centrifugation at 200x g for 10 min at 25°C. After removing the 
supernatant, the cells were re-suspended in complete RPMI medium and adjusted to 
1x106 cells per ml before use.  
HCV detection 
For quantifying HCV genomic copy number in purified total cellular RNA samples, we 
used the primers and probes as previously described (5). Each sample was quantified 
in triplicate using a TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific, 
Waltham, MA) with 10 µl RNA input per reaction in a 50 µl mixture. The reactions were 
carried out on ABI 7900HT system with a program of 50°C for 2 min, 60°C for 30 min, 
95°C for 3 min, and then 50 cycles at 95°C for 20 sec and 60°C for 1 min. The copies of 
HCV RNA were determined by in vitro transcribed HCV1a RNA standards (6) with the 
Sequence Detector Software (version 2.2; Applied Biosystems) and normalized to 1 µg 
total RNA input.  
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Supporting Fig. S1.  Titrating the amount of C3d antibody needed to block HCV binding to 
B cells. Twenty-five µl serum sample was incubated with the indicated amount of mouse 
monoclonal antibody C3d (clone 003-05) at 25°C for 30 min, followed by mixing with virus and 
incubating at 25°C for 1 h. After mixing with PBMC, the mixture was incubated at 25°C for one 
more hour. The cells then were processed for HCV quantification as described in Methods 
section.  Each value represents the mean ± SD of 6 determinations.  
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Supporting Fig. S2.  A combination of purified complement proteins C1, C2, C3, and C4 can 
restore HCV binding activity to B cells. Ten million genomic copies of HCV 1a (H77s) in 3 ml 
medium were incubated with the indicated purified complement protein(s). The amount of each 
protein used was as follows: C1, 25 µg; C2, 5 µg; C3, 60 µg; and C4, 25 µg. For positive control 
serum, 100 µl was used in each reaction.  After 0.5 h incubation at 25°C, 2 ml PBMCs (2.5x107 
cells per ml) in complete RPMI medium was added. The reaction was carried out at room 
temperature (25°C) for 1 h. The cells then were processed for HCV quantification as described 
in Methods section. The values for C1, C2, C3, or C4 only reaction represent the mean ± SD of 
3 determinations. The values for a combination of two or more of C1, C2, C3, or C4 reaction 
represent the mean ± SD of 6 determinations. 
Page 47 of 51
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
8 
 
+  
1 0
 m
g  
Is
o t
y p
e  
c o
n t
ro
l
+  
1 0
 m
g  
A n
ti-
C D
2 1
+  
5  
m g
 Is
o t
y p
e  
c o
n t
ro
l
+  
5  
m g
 A
n t
i-C
D 2
1
+  
1  
m g
 Is
o t
y p
e  
c o
n t
ro
l
+  
1  
m g
 A
n t
i-C
D 2
1
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
T r e a tm e n t
H
C
V
 c
o
p
ie
s 
/m
g
 t
o
ta
l R
N
A
P  <  0 .0 0 0 1
P  <  0 .0 0 0 1
P  =  0 .0 0 0 3
 
Supporting Fig. S3.  Titration of antibody concentration of anti-CD21 (complement 
receptor 2) in complement-mediated HCV binding to B cells. Two ml of PBMCs (2.5x107 
cells/ml) were incubated with the indicated amount of anti-human CD21 antibody (clone 
1048) or isotype control antibody at 25°C for 0.5 h; followed by mixing with 3 ml of 
activated virus (pre-incubation with serum for 0.5 h at 25°C, 1x107 genomic copies 
total), and incubating at 25°C for 1 h. The cells then were processed for RNA isolation 
and HCV quantification as described in Methods section. Each value represents the 
mean ± SD of 6 determinations. 
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Supporting Fig. S4. Lowering the concentration of antibodies to receptors involved in 
complement-mediated HCV binding to B cells. Two ml of PBMCs (2.5x107 cells/ml) 
were incubated with 1 µg of the indicated antibody at 25°C for 0.5 h; followed by mixing 
with 3 ml of activated virus (pre-incubation with serum for 0.5 h at 25°C, 1x107 genomic 
copies total), and incubating at 25°C for 1 h. The cells then were processed for RNA 
isolation and HCV quantification as described in Methods section. Each value 
represents the mean ± SD of 6 determinations. 
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 Supporting Fig. S5. Receptors involved in complement-mediated HCV binding to B 
cells. Two ml of untouched B cells (1.0x106 cells/ml) were incubated with 10 µg of the 
indicated antibody at 25°C for 0.5 h; followed by mixing with 3 ml of activated virus (pre-
incubation with serum for 1 h at 25°C, 1.5x107 genomic copies total), and incubating at 
25°C for 1 h. The cells then were processed for RNA isolation and HCV quantification 
as described in Methods section. Each value represents the mean ± SD of 6 
determinations. The experiments were repeated three times with similar results using 
untouched B cells from three different donors. 
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